Gabelli Funds LLC Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gabelli Funds LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 99.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 367,500 shares of the company's stock after acquiring an additional 183,000 shares during the period. Gabelli Funds LLC's holdings in Teva Pharmaceutical Industries were worth $8,100,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. FMR LLC grew its stake in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP raised its position in Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after buying an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after acquiring an additional 569,412 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock worth $203,642,000 after acquiring an additional 489,041 shares during the period. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.54 during trading on Tuesday, reaching $13.85. The company's stock had a trading volume of 3,982,271 shares, compared to its average volume of 12,367,414. The company's fifty day moving average is $15.39 and its 200-day moving average is $17.65. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market capitalization of $15.71 billion, a P/E ratio of -9.56, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of research analyst reports. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday, April 14th. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.